Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2013 - 02 - 18

Florence, February 18, 2013 - New Board of Directors appointed at Menarini Industrie Farmaceutiche Riunite, parent company of the Menarini Group

Menarini Board of Directors welcomes independent member, Juerg Witmer

Florence, February 18, 2013. The shareholders meeting of Menarini IFR was held today for the renewal of its Board of Directors. In addition to Lucia Aleotti and Alberto Giovanni Aleotti, appointed President and Vice President in representation of the ownership, for the first time an independent non-executive director joins the board: Juerg Witmer, a professional with significant international standing and vast experience in the pharmaceutical industry as well as others.

Dr. Witmer began his career at Roche, where after having served as assistant to the CEO, he acquired valuable knowledge of the Far East markets, spending six years in Hong Kong, first as Marketing Manager and then as General Manager of China.
In 1999 he joined the Givaudan Group, world leader in the fragrance and flavor sector, first as CEO and then as non-executive Chairman (current position). Dr. Witmer is also Vice Chairman of Syngenta (one of the main players in the agri-industry worldwide), and member of the Board of Zuellig, Hong Kong, which is one of the most important pharmaceutical distributors in Asia.

"The addition of Dr. Witmer to the Board of Directors underlines the Menarini Group’s projection towards Asia Pacific, one of the fastest growing areas in the world, where just over one year ago we acquired the Invida Group in 13 countries,” said Lucia Aleotti. “Also, Dr. Witmer’s expertise in multinational companies of various sectors represents a significant added value of knowledge for our company which has always aimed beyond its fundamental principles of internationalization, excellence in the Research and Development of new drugs and quality of drug manufacturing..”

The structure of the Group’s executive governance remains unvaried with its two General Group Managers, Domenico Simone and Pietro Corsa.

Juerg Witmer – Curriculum Vitae

Jürg Witmer is currently Chairman of Givaudan SA, Geneva and Vice Chairman of Syngenta AG, Basel.
Between 2008 to 2012 he was also Chairman of Clariant AG, Basel.
Since 2012 he is a Member of the Board of the Zuellig Group, Hong Kong. Jürg Witmer is also a former Board Member of Crucell N.V., Leiden, NL and of Bank Sal. Oppenheim Cie, AG, Zürich
After a student exchange year in California, Jürg Witmer studied political science at Geneva University’s Graduate Institute and law at the University of Zurich, and he was admitted to the Swiss Bar.
In 1978, he joined Hoffmann- La Roche in Basel as legal counsel and subsequently as assistant to the Chairman and CEO. In 1984, he moved to Roche Far East in Hong Kong where he held the positions of China Project Manager, Regional Marketing Manager and General Manager.
In 1990, he returned to Basel as Head of Corporate Communications and Public Affairs, for the Roche Group.
In 1994, he moved to Vienna as General Manager of Roche, Austria.
In 1999 he was appointed the CEO of Givaudan Group in Geneva.
Since 2005 Jürg Witmer is the non-executive Chairman of the Givaudan Group.

About Menarini Group

Menarini, headquarters of the Menarini Group, was founded Naples in 1886 and then moved to Florence in 1915.

Today it is the leading Italian pharmaceutical company in the world, ranking 17th in Europe and 34th in the world (IMS World Review 2012).

Present in over 100 countries throughout the world, today it counts 16, 640 employees and has a 2012 turnover of over €3 billion.
Research and internationalization represent the main areas of strategic development for its future.

The Group has 14 manufacturing sites located in Italy and abroad where over 545 million packages/year are produced and distributed throughout the five continents, thus allowing Menarini to contribute to the health of patients all over the world with its high quality standards.

For further information contact : Menarini Group Press Office